PRECIRIX
6.10.2021 13:02:09 CEST | Business Wire | Press release
Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, announces that it has dosed the first patients in its Phase I/II clinical study of CAM-H2 for the treatment of HER2-positive metastatic cancer. This is a major milestone in the company’s development of its lead therapeutic asset.
The Phase I/II trial (NCT04467515 ) evaluates safety, tumor uptake, tumor retention and early signs of antitumor activity of single-agent CAM-H2 in HER2-positive metastatic breast and gastric/gastro-esophageal cancer patients that have relapsed or are refractory to available anti-HER2 therapies. The trial is a continuous study composed of two parts: a Phase I dose-escalation phase to establish the recommended dose for Phase II in 3+3 dose-ascending cohorts of patients, followed by a Phase II dose-expansion phase. The Phase I/II clinical study will allow inclusion of patients with brain metastases, a population in dire need of effective therapies, and will enroll a total of appr. 70 patients.
Ruth Devenyns, CEO commented: “We are very excited to have dosed the first patients in this clinical study, the result of years of thorough scientific research, collaboration and operational excellence of our entire team and partners. Special thanks to our former CMO Ruggero Della Bitta, for his contribution to our global clinical development strategy and securing regulatory clearance for the Phase I/II trial. We look forward to recruiting additional patients and generating efficacy data to confirm the strong results from our preclinical and first-in-human studies, with the goal of bringing new treatment options to cancer patients.”
About CAM-H2
CAM-H2 comprises a single-domain antibody targeting HER2, covalently linked to iodine-131. Single-domain antibodies are ideally suited for targeted delivery of radiation to tumors given their size, specificity and pharmacokinetic characteristics. Imaging studies conducted with the HER2 targeting single-domain antibody labelled with gallium-68 have demonstrated specific uptake and retention in primary, metastatic and brain lesions in HER2-positive breast cancer patients.
About HER2-positive cancer
Worldwide, >1.6 m cases of breast cancer and >1.2m cases of gastric cancer are diagnosed annually, of which >20% are HER2-positive. In breast cancer, some 60% of the patient population develops metastatic disease, with brain metastases occurring in up to 50% of metastatic patients1,2 . HER2 is also overexpressed in subsets of patients with other solid tumors including biliary tract, colorectal, non-small-cell lung and bladder cancer3 .
HER2 is an established therapeutic target and a variety of agents targeting HER2 have been approved, however none of these cure metastatic disease. Specifically in brain metastases there are limited treatment options. There are no approved HER2 targeting radiopharmaceuticals and CAM-H2 is the lead candidate in therapeutic development, leveraging the advantages of using a single-domain antibody to deliver targeted radiation to the tumor and bringing a new mechanism of action in the current HER2 treatment landscape to address important unmet medical needs, including brain metastases and low HER2 expression.
About Precirix NV
Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labeled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’ technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a higher therapeutic dose for treatment.
1
‘From diagnosis to treatment: Understanding breast cancer’, Roche website
2
‘Real-world characteristics metastatic breast cancer’ (ASCO 2018)
3
Oh et al. Nature Reviews Clinical Oncology
2019
View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005529/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Expands GeoPurchase Audiences Globally, Unlocking Growth Opportunities for Marketers in Poland, Belgium, Mexico, and Indonesia22.6.2026 12:00:00 CEST | Press release
International expansion helps advertisers target audiences based on local consumer demand NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the expansion of its GeoPurchase audiences into Poland, Belgium, Mexico, and Indonesia, extending its purchase-based, geo-targeted audiences to new international markets. As privacy regulations tighten and identifiers like cookies decline, marketers need new ways to reach high-value consumers at scale. NIQ’s GeoPurchase Audiences address this challenge by helping marketers identify and target consumers based on demand, not just demographics. GeoPurchase audiences help marketers pinpoint geographic areas where consumers are most likely to purchase specific FMCG categories, brands, or sub-brands, so media investments can concentrate where retail opportunities are strongest. By focusing investments in priority locations, marketers can connect with the audiences that matter in the markets with the greatest opportunity. As a resu
Smartly Introduces Smartly Synapse, the Intelligent AI Orchestration Layer Powering Its Advertising Platform22.6.2026 12:00:00 CEST | Press release
Smartly Synapse powers Smartly’s agentic orchestration, providing marketers a faster, more intelligent way to plan, execute, and optimize millions of signals for better results Smartly today introduced Smartly Synapse, the intelligent AI orchestration and memory layer behind every Smartly AI Agent. Built on years of cross-channel creative, media and performance intelligence and continuously shaped by real-world outcomes, Smartly Synapse transforms millions of signals into actions that help marketers plan smarter, execute faster and drive stronger business results. Smartly Synapse creates a continuous performance loop where marketer intent, business context, campaign activity and outcomes continuously inform one another. Its shared intelligence and memory layer helps the system learn from every campaign, improving future recommendations, execution and performance. “Smartly Synapse is the intelligent AI orchestration and memory layer behind our AI agents. It augments Smartly’s existing p
Europe’s Original First Check Investor Seedcamp Raises $320 Million22.6.2026 11:23:00 CEST | Press release
First backer of Revolut, Wise, UiPath, Synthesia and Fluidstack brings nearly two decades of experience and conviction to Europe’s next frontier Expands US team to support founders building global giants from day one Raise is split across a $220m Core fund and $100m Select fund to back winners through Series B and beyond Backing founders at the very beginning - before the company or the theme is obvious Seedcamp, Europe’s original first check investor and earliest backer of companies including Revolut, Wise, UiPath, Synthesia and Fluidstack, has raised $320 million to invest in the next generation of global companies. US expansion for born global founders and early growth capital for portfolio winners Since launching in 2007 with a $2.5m first fund, Seedcamp now manages over $1bn in AUM and has delivered some of the strongest venture fund returns in Europe. Seedcamp Fund III has now returned over 13x DPI to its Limited Partners, and Fund IV sits at over 5x net TVPI. The new capital is
Navan Invests in European Footprint with New Partnerships22.6.2026 10:01:00 CEST | Press release
New integrations with ITA Airways, Caledonian Sleeper, and Virtuo elevate localized inventory across Europe Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced new integrations with European travel suppliers. Navan will add to its platform a direct New Distribution Capability (NDC) connection with Italy’s national air carrier, ITA Airways; overnight rail services in the UK with Caledonian Sleeper; and mobile-first car rental bookings in France with Virtuo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622904121/en/ New integrations with ITA Airways, Caledonian Sleeper, and Virtuo elevate localized inventory across Europe “We’re seeing incredible momentum across Europe, bookings to and from the continent are up year-over-year, and to truly serve the European market you have to continually invest locally,” said Michael Riegel, Chief Customer Officer at Navan. “By bringing ITA’s
Finalists Announced for the Second Edition of the Reply AI Music Contest, the International Competition Exploring the Relationship Between AI and Live Performance22.6.2026 10:00:00 CEST | Press release
The jury will announce the winners on Saturday, 4 July, on the stage of Kappa FuturFestival in Turin Music and artificial intelligence come together at the Reply AI Music Contest to explore the relationship between AI and live performance. The competition, created by Reply and organized in collaboration with Kappa FuturFestival — one of Europe’s leading festivals dedicated to electronic music and cultural innovation — announces the five finalists selected by an international jury of professionals from music and creative industries: Agoria, Max Cooper, Fleur Shore, Tini Gessler, Ali Demirel, Albi Scotti, Oliver Bohl and Sarah Grimaldi. The finalists represent a new generation of innovators using AI to explore new forms of integration between sound, visual arts and live performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622111182/en/ Finalists announced for the second edition of the Reply AI Music Contest, the inte
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom